Maravai LifeSciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Maravai LifeSciences (MRVI).

Price Target Range — 11 Quarters

Analyst Consensus — 9 Analysts

5Buy

3Hold

1Sell

Consensus RatingBuy# Analysts9Avg. Consensus PT$6Upside to Avg. PT-20.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	UBS	Dan Brennan	PT Raise	Neutral	$3→$8
Aug 7, 2026	Wells Fargo	Evan Stampler	PT Raise	Overweight	$6→$7
May 8, 2026	Wells Fargo	Brandon Couillard	PT Raise	Overweight	$5→$6
Dec 15, 2025	Wells Fargo	Brandon Couillard	PT Raise	Overweight	$4→$5
Aug 12, 2025	Craig-Hallum	Christian Schwab	PT Cut	Buy	$10→$5
Aug 12, 2025	RBC Capital	Conor McNamara	PT Cut	Outperform	$7→$5
May 13, 2025	Craig-Hallum	Christian Schwab	PT Cut	Buy	$12→$10
May 13, 2025	Baird	Catherine Schulte	PT Cut	Neutral	$3→$2
Mar 25, 2025	Morgan Stanley	Tejas Savant	PT Cut	Equal-Weight	$7→$5
Mar 21, 2025	UBS	Dan Brennan	PT Cut	Neutral	$8→$3
Mar 3, 2025	B of A Securities	Michael Ryskin	PT Cut	Buy	$9→$8
Feb 26, 2025	Baird	Catherine Schulte	Downgrade	Outperform→Neutral	$9→$3
Dec 5, 2024	Goldman Sachs	Matthew Sykes	Downgrade	Neutral→Sell	$7→$4
Nov 14, 2024	Wolfe Research	Doug Schenkel	Initiate	Peer Perform	—
Nov 8, 2024	RBC Capital	Conor McNamara	PT Cut	Outperform	$17→$13
Nov 8, 2024	William Blair	Matt Larew	Downgrade	Outperform→Market Perform	—
Nov 8, 2024	Baird	Catherine Schulte	PT Cut	Outperform	$10→$9
Oct 8, 2024	Goldman Sachs	Matthew Sykes	PT Cut	Neutral	$8→$7
Aug 27, 2024	Wells Fargo	Brandon Couillard	Initiate	Overweight	$10
Aug 16, 2024	RBC Capital	Conor McNamara	Maintained	Outperform	$15

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

UBS analyst Dan Brennan maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and raises the price target from $2.5 to $8.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

Wells Fargo analyst Evan Stampler maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $5.5 to $6.5.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

Wells Fargo analyst Brandon Couillard maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $4.5 to $5.5.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

Wells Fargo analyst Brandon Couillard maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $4 to $4.5.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5

RBC Capital analyst Conor McNamara maintains Maravai LifeSciences (NASDAQ:MRVI) with a Outperform and lowers the price target from $7 to $5.

Benzinga Newsdesk

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

Avi Kapoor

Maravai LifeSciences Holdings Inc

Maravai LifeSciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRO
RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

People Also Watch

People Also Watch

Maravai LifeSciences Holdings Inc

Maravai LifeSciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROUBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PROWells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRORBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5

These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results

People Also Watch

People Also Watch

PRO
UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5

PRO
Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $4.5

PRO
RBC Capital Maintains Outperform on Maravai LifeSciences, Lowers Price Target to $5